NVCA Jumps Into the Healthcare Reform Debate PDF Print E-mail
Sunday, September 07 2008

The NVCA Medical Industry Group is in the process of drafting healthcare reform principals in preparation for the debate that will most likely become a top priority for the new Administration and Congress next year.

NVCA supports comprehensive reform of the U.S. healthcare system in order to provide coverage to all Americans, improve quality of care, and control increasing health care costs. A comprehensive health care reform policy will eliminate inefficiencies and disincentives that fragment the current system. Chief among the necessary reforms for NVCA will be to change the coverage and payment policies necessary to facilitate wide-spread adoption of therapies and products that improve health care quality and reduce overall health care costs. NVCA wants to ensure that all patients will have access to new life saving products.

The following are the key draft principals NVCA believes should be included in any comprehensive health reform plan.

Expand Access to Medical Care and Innovative Technologies

Any health reform proposal must afford all Americans access to health insurance coverage that includes all appropriate medical treatments, therapies and services.

NVCA is committed to an evidence-based medicine approach that generates clinically meaningful data to better inform patients and physicians about important new therapeutics, medical technologies, and diagnostics that prevent illness, fight disease, and improve quality of care. Coverage and payment policies will play an increasingly critical role in the development of new innovative therapies and products.

Value Based Payment for Innovation

Comprehensive health reform should modernize the payment system to ensure that payment methodology is based on value and supports and sustains innovative new technologies.

Enhance Predictability and Transparency in Regulatory Processes

For investors in the health care field there needs to be more transparency in the regulatory process, otherwise funds for investment in novel therapies and technologies will be shifted to other sectors with less risk.
 

February 2012